235 related articles for article (PubMed ID: 24344786)
1. Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds.
Devalapally H; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ; Silchenko S
Drug Deliv; 2015; 22(4):467-74. PubMed ID: 24344786
[TBL] [Abstract][Full Text] [Related]
2. Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation.
Cheng Y; Liu M; Hu H; Liu D; Zhou S
AAPS PharmSciTech; 2016 Apr; 17(2):409-17. PubMed ID: 26195071
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.
Devalapally H; Silchenko S; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ
J Pharm Sci; 2013 Oct; 102(10):3808-15. PubMed ID: 23878097
[TBL] [Abstract][Full Text] [Related]
4. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
Feeney OM; Williams HD; Pouton CW; Porter CJ
J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
[TBL] [Abstract][Full Text] [Related]
5. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation.
Đorđević SM; Cekić ND; Savić MM; Isailović TM; Ranđelović DV; Marković BD; Savić SR; Timić Stamenić T; Daniels R; Savić SD
Int J Pharm; 2015 Sep; 493(1-2):40-54. PubMed ID: 26209070
[TBL] [Abstract][Full Text] [Related]
6. Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil.
Alayoubi A; Alqahtani S; Kaddoumi A; Nazzal S
AAPS J; 2013 Oct; 15(4):1168-79. PubMed ID: 23990503
[TBL] [Abstract][Full Text] [Related]
7. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model.
Fraga M; Bruxel F; Diel D; de Carvalho TG; Perez CA; Magalhães-Paniago R; Malachias Â; Oliveira MC; Matte U; Teixeira HF
J Control Release; 2015 Jul; 209():37-46. PubMed ID: 25886705
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
Gill KK; Nazzal S; Kaddoumi A
Eur J Pharm Biopharm; 2011 Oct; 79(2):276-84. PubMed ID: 21575719
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability.
Zeng N; Hu Q; Liu Z; Gao X; Hu R; Song Q; Gu G; Xia H; Yao L; Pang Z; Jiang X; Chen J; Fang L
Int J Pharm; 2012 Mar; 424(1-2):58-66. PubMed ID: 22240390
[TBL] [Abstract][Full Text] [Related]
10. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
11. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
12. A noticeable phenomenon: thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats.
Wang C; Cheng X; Sui Y; Luo X; Jiang G; Wang Y; Huang Z; She Z; Deng Y
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):744-51. PubMed ID: 24129310
[TBL] [Abstract][Full Text] [Related]
13. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
14. Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: preparation, characterisation and in vitro evaluation.
Zariwala MG; Farnaud S; Merchant Z; Somavarapu S; Renshaw D
Colloids Surf B Biointerfaces; 2014 Mar; 115():86-92. PubMed ID: 24333557
[TBL] [Abstract][Full Text] [Related]
15.
Dhande R; Tyagi A; Sharma RK; Thakkar H
Pulm Pharmacol Ther; 2018 Apr; 49():36-45. PubMed ID: 29337265
[TBL] [Abstract][Full Text] [Related]
16. Ascorbyl dipalmitate/PEG-lipid nanoparticles as a novel carrier for hydrophobic drugs.
Moribe K; Maruyama S; Inoue Y; Suzuki T; Fukami T; Tomono K; Higashi K; Tozuka Y; Yamamoto K
Int J Pharm; 2010 Mar; 387(1-2):236-43. PubMed ID: 20005934
[TBL] [Abstract][Full Text] [Related]
17. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
18. Mixed PEGylated surfactant modifying system decrease the accelerated blood clearance phenomenon of nanoemulsions in rats.
Su Y; Tang W; Song Y; Wang C; Tian Q; Wang X; Quan J; Li B; Wang S; Deng Y
Asian J Pharm Sci; 2017 Jan; 12(1):28-36. PubMed ID: 32104311
[TBL] [Abstract][Full Text] [Related]
19. Composition-dependent structural changes and antitumor activity of ASC-DP/DSPE-PEG nanoparticles.
Higashi K; Mibu F; Saito K; Limwikrant W; Yamamoto K; Moribe K
Eur J Pharm Sci; 2017 Mar; 99():24-31. PubMed ID: 27916697
[TBL] [Abstract][Full Text] [Related]
20. Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona.
Li Z; Han X; Zhai Y; Lian H; Zhang D; Zhang W; Wang Y; He Z; Liu Z; Sun J
Colloids Surf B Biointerfaces; 2015 Jun; 130():133-40. PubMed ID: 25907597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
